Navigation Links
IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Date:3/27/2008

TORONTO, March 27 /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware) is pleased to announce significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics Corp. of Toronto ("IntelliPharmaCeutics" or the "Company"). The product is covered by pending patent applications for its novel ReXista(TM) abuse and alcohol resistant drug delivery technology. It is one of the Company's line of in-house analgesic products in development for the management of moderate to severe chronic and acute pain.

The ReXista(TM) oxycodone product is a novel dosage form, designed to be resistant to abuse by oral ingestion when crushed or chewed, by injection when combined with solvents, and by nasal application when crushed or powdered. The abuse of this important pain relief drug has been well documented over many years.

The ReXista(TM) oxycodone product is also designed to resist release of the entire daily dose when consumed with alcohol in any quantity, a problem so serious with some opioid drugs such as hydromorphone that their use has been limited or curtailed by the FDA.

The product has been subjected to rigorous in-vitro testing and has met its design criteria for dissolution profiles and in-vitro resistance to simulated abuse. Based on these initial results, the product is expected to be effective for once-a-day dosing in the management of pain. It is also expected that it will resist abuse by oral, nasal or intravenous administration and resist unintended total dose release in the presence of alcohol.

The initial pilot clinical trial was designed to compare the pharmacokinetic characteristics of the IntelliPharmaCeutics ReXista(TM) oxycodone product, in a once-a-day 40mg dosage format, with a currently marketed branded oxycodone product, Purdue Pharma's Oxycontin(R), in a twice-a-day 20mg dosage format, under fasted conditions.
The pilot clinical trial produced the following results:

- The ReXista(TM) product demonstrated sustained release

pharmacokinetic activity, with blood plasma concentrations at

clinically significant levels over a 24 hour period.

- The bioavailability of a single dose of the ReXista(TM) product, as

measured by Cmax and AUC, was comparable to that of two doses of

Oxycontin(R) dosed at 12 hour intervals. Both Cmax and AUC were in

the 80% - 125% range as compared to Oxycontin(R), demonstrating

effective bioequivalence with the branded product.

The Company intends to release detailed results of this pilot clinical trial after further study and analysis. Dr. Isa Odidi, CEO and Chief Design Officer for IntelliPharmaCeutics, stated "We are very encouraged by these early results. The ReXista(TM) delivery technology was developed entirely in-house, and is unique in the industry. We are excited that our new ReXista(TM) dosage form, which resists dose-dumping in the presence of alcohol, and which has great potential to resist oral, nasal and intravenous abuse, has already demonstrated controlled release to a once-a-day standard and effective bioequivalence with the twice daily branded product. With these results in hand, we will certainly move rapidly to advance the development into a full clinical trial program. We will also now apply the Rexista(TM) technology to other narcotic analgesic agents in our development pipeline."

About IntelliPharmaCeutics

--------------------------

IntelliPharmaCeutics is a drug delivery innovator and developer, specializing in the controlled and targeted once-a-day delivery of oral, solid dose pharmaceutical products. It operates from a 25,000 sq ft research laboratory and manufacturing scale-up facility located adjacent to Toronto International Airport. The Company utilizes proprietary, patented and proven drug delivery technologies, to formulate both generic and new drug products with enhanced performance characteristics. In addition to its pre-clinical portfolio, IntelliPharmaCeutics has an extensive pipeline of development products in clinical trials, in therapeutic areas that include neurology, cardiovascular, GIT, and pain. For more information about IntelliPharmaCeutics, visit the Company's web site at http://www.intellipharmaceutics.com.

This news release contains forward-looking statements, including those related to the preliminary nature of clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of IntelliPharmaCeutics, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future clinical testing and regulatory review will be required prior to marketing approval, there can be no certainty that a successful commercial product will be developed. The Company undertakes no obligation to update any forward-looking statements.


'/>"/>
SOURCE IntelliPharmaCeutics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... ... 2016 , ... A new study published in the just-published ... advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue ... sampling may improve the value of a blood-based test.” The study was conducted ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):